scPharmaceuticals
SCPH
SCPH was delisted on the 6th of October, 2025.
88 hedge funds and large institutions have $98.7M invested in scPharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 33 increasing their positions, 26 reducing their positions, and 8 closing their positions.
2,977% more call options, than puts
Call options by funds: $400K | Put options by funds: $13K
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
27% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 26
4% more funds holding
Funds holding: 85 → 88 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4.82% less ownership
Funds ownership: 79.49% → 74.67% (-4.8%)
30% less capital invested
Capital invested by funds: $141M → $98.7M (-$42.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
+$2.99M |
| 2 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$1.33M |
| 3 |
Luther King Capital Management (LKCM)
Fort Worth,
Texas
|
+$857K |
| 4 |
KCM
Kingdon Capital Management
New York
|
+$651K |
| 5 |
ACA
Apis Capital Advisors
New York
|
+$361K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
-$6.52M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$2.31M |
| 3 |
JGC
J. Goldman & Co
New York
|
-$2.06M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.09M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$1.05M |
SCPH Hedge Fund Activity: Q1 2025 in Review
88 of the 7,471 institutional investors tracked by Wall St. Rank reported a position in scPharmaceuticals (SCPH) for Q1 2025, worth a combined $98.7M — down 30% from $141M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new SCPH positions and 8 closed out — a net gain of 3 holders — while 33 added to existing stakes and 26 trimmed.
The largest buyer was Velan Capital Investment Management, opening a new position worth an estimated $2.99M. The largest seller was Suvretta Capital Management, exiting entirely with an estimated $6.52M sold.
- 88 institutional investors held scPharmaceuticals (SCPH) as of Q1 2025, up from 85 in Q4 2024.
- Funds reported $98.7M of scPharmaceuticals stock for Q1 2025, down 30% quarter-over-quarter.
- 11 funds opened new scPharmaceuticals positions in Q1 2025 and 8 closed out, a net change of +3 holders.
- The largest scPharmaceuticals buyer in Q1 2025 was Velan Capital Investment Management, an estimated $2.99M added.
- The largest scPharmaceuticals seller in Q1 2025 was Suvretta Capital Management, an estimated $6.52M sold.
Based on aggregated 13F filings for Q1 2025.